phorylation on serine 68 (S68) [2, 3] while protein kinase C (PKC) induces phosphorylation on both serine 63 (S63) and S68 [2, 3] . Initial studies suggested a role for PLM in osmolyte fl ux and cell volume regulation [4, 5] . More recent fi ndings suggest a physical and functional association of PLM with membrane ion transporters such as the Na,K-ATPase [6, 7] and the Na-Ca exchanger (NCX1) [8, 9] . These fi ndings suggest that PLM may have functional roles similar to other members of the FXYD family of proteins [10] . For example, the ␥ -subunit of Na,KATPase (FXYD2) shares signifi cant homology with PLM [10] that could explain the effect of PLM on Na,K-ATPase activity [11] .
Very little is known about PLM in smooth muscle. Three papers describe a 16-to 17-kDa phosphoprotein in smooth muscle that may well have been PLM (PLM has an apparent molecular weight of approximately 16 kDa on SDS gels) [1] . In 1985, Boulanger-Saunier et al. [12] identifi ed a 16-kDa phosphoprotein in a plasma membrane-enriched fraction of rat aortic smooth muscle cell membranes. This protein copurifi ed with Na,K-ATPase and was phosphorylated by PKA in vitro and by isoproterenol in vivo. Its dephosphorylation was inhibited by 10 m M NaF. Boulanger-Saunier et al. [13] subsequently found that a phorbol ester (TPA) in vitro and arginine vasopressin in vivo induced phosphorylation of the 16-kDa protein on a second site distinct from the PKA site. In 1989, Sarevic et al. [14] found that a 17-kDa membrane phosphoprotein, likely PLM, was phosphorylated by PKA but not by protein kinase G. PLM mRNA has been reported in canine aortic, esophageal and gastric smooth muscle [1] . While these publications suggest that PLM is present and phosphorylated in intact smooth muscle, they cannot be considered defi nitive as they predate the cloning of PLM in 1991 and the subsequent development of reagents to study it.
Contraction of smooth muscle is typically associated with increased intracellular [Ca 2+ ] ( [Ca 2+ ] i ), formation of a Ca 2+ 4 -calmodulin complex, activation of myosin light chain kinase (MLCK) and phosphorylation of myosin regulatory light chains (MRLC) on serine 19 [15] . Phosphorylation of MRLC enables crossbridge attachment to the thin fi lament, thereby allowing crossbridge cycling and force generation [16] . In many cases, smooth muscle relaxation proceeds via a reversal of this contraction process: reduction of myoplasmic [Ca 2+ ], inactivation of MLCK and dephosphorylation of MRLC [17] [18] [19] .
cAMP-mediated smooth muscle relaxation occurs via binding of agonists to specifi c seven-membrane-spanning receptors (e.g., ␤ 2 -adrenergic) which activate adenylyl cy- infl ux through voltage-gated channels [24] , and (4) activation of plasma membrane Ca 2+ pumps [25] . There are also mechanisms other than reductions in [Ca 2+ ] i where increased [cAMP] can cause relaxation, e.g., force suppression associated with serine 16 heat shock protein 20 phosphorylation [26] .
Our general hypothesis is that cAMP-mediated phosphorylation of PLM on S68 phosphorylation causes vascular smooth muscle relaxation by increasing the activity of the Na,K-ATPase. The goals of this study were (1) to determine if PLM is present in smooth muscle, (2) to determine if cAMP-mediated relaxation is associated with S68 PLM phosphorylation, the site phosphorylated by PKA in vitro, and (3) to infer whether cAMP-mediated relaxation is associated with a decrease in intracellular Na + ([Na + ] i ). To accomplish these goals, we developed S68 phosphorylation-specifi c PLM antibodies. These antibodies were then tested in forskolin-induced relaxation of swine carotid artery.
Material and Methods

Tissues
Swine common carotid arteries were obtained from a slaughterhouse and transported at 0 ° C in physiological salt solution (PSS). PSS contained (m M ): NaCl 140, KCl 4.7, 3-[N-morpholino] propane sulfonic acid 5, Na 2 HPO 4 1.2, CaCl 2 1.6, MgSO 4 1.2, D -glucose 5.6, pH adjusted to 7.4 at 37 ° C. Zero Na + PSS was PSS where CholineCl was substituted for NaCl and the Na 2 HP0 4 was omitted. Dissection of medial strips, mounting and determination of the optimum length for stress development at 37 ° C were performed as previously described [27] . The intimal surface was mechanically rubbed to remove the endothelium.
Antibodies
We developed two specifi c antibodies against PLM: C2 which was made to react with dephosphorylated PLM and CP68 which was made to react with PLM phosphorylated at S68, the site phosphorylated by PKA. Both were raised against C-terminal PLM peptides. To raise polyclonal antibodies against dephosphorylated PLM (C2), the 16-amino acid peptide NH 2 -CGTFRSSIRRLSTR RR-COOH was used as the antigen and the resulting rabbit polyclonal antibody affi nity purifi ed as described [28] . To make S68 phosphorylation-specifi c antibodies (CP68), the 19-amino acid peptide NH 2 -DEEEGTFRSSIRRL Sp (68) TRRR-COOH was made with phosphoserine (Sp) at S68. This peptide was injected into rabbits and serum collected. For affi nity purifi cation of CP68 (the phosphorylation-specifi c antibody), the serum was processed over an agarose immunosorbent containing the unconjugated dephosphorylated peptide to remove antibody activity that would bind the peptide irrespective of phosphorylation status. Phosphorylated PLM-specifi c antibodies were then affi nity purifi ed from the cleaned serum by passage over an immunosorbent containing the phosphorylated PLM peptide. ELISA showed less than 2% cross reactivity of the phosphorylated PLM-specifi c antibody with the dephosphorylated PLM peptide (Bethyl Labs, Montgomery, Tex., USA).
PLM Standards
Purifi ed recombinant dephosphorylated PLM was prepared as described [29] . A pig cardiac sarcolemmal vesicle preparation [30] was loaded on most blots since it contained dephosphorylated and phosphorylated PLM that was detected by both anti-PLM antibodies.
PLM in vitro Phosphorylation
Forty micrograms of purifi ed recombinant dephosphorylated PLM (trifl uorethanol removed by N 2 evaporation) [29] were incu- 
Measurement of PLM Phosphorylation
Swine carotid arteries were pharmacologically treated and frozen in an acetone-dry ice slurry (20 g/20 ml) at -78 ° C [27] . The frozen tissue was allowed to slowly thaw to room temperature in the slurry (2 h), the tissues were air dried, weighed and homogenized in a buffer containing 1% SDS, 10% glycerol and 20 m M dithiothreitol (20 mg wet weight/ml buffer). Twenty microliters of homogenates (concentration normalized to tissue weight) were then loaded identically onto two 12% SDS electrophoresis gels, blotted to nitrocellulose and then incubated with the anti-PLM antibodies (1: 10,000 for C2 and 1: 1,000 for CP68). After washing, incubation with secondary antibodies (1: 5,000 of goat anti-rabbit) and detection with enhanced chemiluminescence, the blots were imaged and digitized with UnScanIt (Silk Scientifi c Inc.).
Two internal standards were loaded on every gel to allow comparison of immunoblotting intensity on different blots. One standard, 'KF', was a pooled homogenate of swine carotid tissues that The intensity of the PLM antibody immunoreactivity was determined for the experimental samples and these standards on every blot. We found that the ratio of the intensity of experimental sample CP68 immunoblotting to the intensity of KF immunoblotting from the same blot was the most reproducible for CP68 (similar results were seen with other normalizations); therefore, we report the CP68/KF ratio as an index of S68-PLM phosphorylation ( fi g. 3 b, d). We found that the C2 blots were most reproducible when the intensity of sample C2 immunoblotting was normalized to the intensity of the C2 immunoblotting from the unstimulated control swine carotid artery tissue from the same blot; therefore, we report the C2/ control ratio as an index of unphosphorylated PLM ( fi g. 3 a, c).
Statistics
The signifi cance of the correlation between the intensity of CP68 immunoblotting and contractile force shown in fi gure 4 was tested using analysis of covariance (ANCOVA). The analysis showed no signifi cant difference among the slopes for different experimental conditions, so the fi nal model allowed intercepts but not slopes to vary. Signifi cance was defi ned as p ! 0.05.
Results
As detailed in the methods, two antibodies were made to C-terminal PLM peptides. To evaluate the specifi city of these antibodies, purifi ed recombinant PLM [29] (shown to be dephosphorylated by mass spectrometry) was phosphorylated with the catalytic subunit of PKA in the presence of ␥ -32 P-ATP. Different amounts of phosphorylated and dephosphorylated PLM (exposed to ␥ -32 P-ATP without PKA) were loaded on SDS gels, blotted, analyzed for 32 P activity and immunoblotted with both antibodies. Increasing 32 P activity was observed with an increasing amount of PKA-treated PLM ( fi g. 1 , top panel). Calculated stoichiometry revealed that approximately 50% of PLM was phosphorylated by PKA treatment (a time course suggested we had reached steadystate phosphorylation). Dephosphorylated PLM was not detected by the CP68 antibody ( fi g. 1 , second panel). The intensity of the CP68 antibody signal was proportional to the amount of PKA-treated PLM loaded on the immunoblot ( fi g. 1 , third panel). The intensity of the C2 antibody signal was proportional to the amount of dephosphorylated PLM loaded on the immunoblot ( fi g. 1 , fourth panel). The intensity of the C2 antibody signal was less intense on immunoblots loaded with PKA-treated PLM ( fi g. 1 , bottom panel) compared with that observed with dephosphorylated PLM.
Swine carotid medial smooth muscle rings were fi rst After an additional 30 min, tissues were frozen and homogenized. Proteins were separated on SDS gels and the intensity of immunoreactiv-ity to the two PLM antibodies determined on immunoblots. As detailed in 'Material and Methods', the intensity of both the C2 and CP68 antibodies were normalized to internal standards. For clarity, the term 'C2 signal' will refer to the intensity of the C2 antibody immunoreactivity normalized to the intensity of the C2 antibody immunoreactivity from the untreated control tissue homogenate loaded on the same blot. Similarly, the term 'CP68 signal' will refer to the intensity of the CP68 antibody immunoreactivity normalized to the intensity of the CP68 antibody immunoreactivity from the KF pooled homogenate loaded on the same blot.
This normalization procedure allows comparison of changes in the C2 and CP68 antibody intensity on different immunoblots. Figure 2 shows a representative immunoblot of tissues stimulated with histamine, and fi gure 3 shows aggregate data. PLM was present in swine arterial smooth muscle, and its phosphorylation status depended on the treatment. Unstimulated (control) tissues had low levels of CP68 signal and force ( fi g. 2 , lane 2; fi g. 3 , fi lled symbols). Histamine (10 M ) induced a large decrease in the C2 signal, a small increase in the CP68 signal and a maximal contraction ( fi g. 2 , lane 3; fi g. 3 , open squares). Adding forskolin to histamine-stimulated tissues was associated with no change in the C2 signal, dose-dependent increases in the CP68 signal ( fi g. 2 , lanes 4-7) and dose-dependent reduction in force ( fi g. The relation between the CP68/KF ratio and active force is shown in fi gure 4 . There was a highly signifi cant negative correlation between the CP68 signal and force (r 2 = 0.5; p ! 0.0001, ANCOVA ] i and less contraction. We evaluated the effect of forskolin pretreatment on swine carotid artery contraction induced by a zero Na + saline in the presence of 10 M diltiazem ( fi g. 6 ). Pretreatment with 1 M forskolin for 15 min signifi cantly reduced the zero Na + contraction compared with a control that was not treated with forskolin. 
Discussion
We found PLM immunoreactivity in smooth muscle ( fi g. 2 ). These data suggest that the 16/17-kDa phosphoprotein identifi ed in smooth muscle plasma membrane preparations [12] [13] [14] was likely PLM. We found that the CP68 PLM signal correlated with cAMP-, but not cGMPmediated relaxation ( fi g. 3, 5 ) . These data suggest a potential role for S68 PLM phosphorylation in cAMP-, but not cGMP-mediated relaxation. The CP68 PLM signal was increased by histamine stimulation but not high 
PLM Antibody Specifi city
Our results suggest that the CP68 antibody detects S68 PLM phosphorylation. PKA treatment of recombinant PLM increased the CP68 signal ( fi g. 1 ). Since dephosphorylated PLM did not produce a CP68 signal, we suggest that the CP68 antibody is specifi c to phosphorylated PLM. However, we cannot state that the CP68 antibody is absolutely specifi c to S68 because we could not make PLM that was only phosphorylated on S63 (there is no kinase that specifi cally phosphorylates PLM on S63).
The specifi city of the C2 antibody could not be clearly delineated either, since PKA treatment induced only approximately 50% phosphorylation. Nevertheless, the C2 signal decreased by approximately 50% with PKA treatment, suggesting that the C2 antibody is at least partially specifi c to dephosphorylated PLM over phosphorylated PLM. Similar results were seen in intact swine carotid: forskolin treatment increased the CP68 signal and decreased the C2 signal ( fi g. 2 ). We found it important to use large dilutions (1: 10,000) of the C2 antibody to detect the fall in the C2 signal when PLM was phosphorylated. These results confi rm and extend those of Silverman et al. [33] who evaluated the C2 and CP68 immunoreactivity in forskolin and phorbol ester-treated rat cardiac myocytes. Both studies agree that PKA activation leads to an increase in the CP68 signal and a decrease in the C2 signal.
Histamine alone induced a large decrease in the C2 signal with only a small increase in the CP68 signal ( fi g. 3 ) . This suggests that histamine alone may have caused phosphorylation of PLM on sites other than S68. These sites may include S63 phosphorylated by PKC [2, 3] or other sites phosphorylated by other kinases. Supporting this contention was the fi nding that addition of forskolin to histamine increased in the CP68 signal without further decreases in the C2 signal. Perhaps forskolin-induced S68 PLM phosphorylation (detected by CP68) on PLM already phosphorylated at other sites (possibly S63) so that there was no change in the C2 signal. The results with high K + -depolarized tissues support this contention; there was no change in the C2 signal with high K + alone, consistent with a lack of PKC activation with high K + . After high K + activation, forksolin decreased the C2 signal and increased the CP68 signal, consistent with the C2 antibody detecting the decline in unphosphorylated PLM and CP68 detecting the S68 phosphorylation. These data suggest that forskolin can induce S68 PLM phosphorylation regardless of PLM phosphorylation at other sites. . This may be related to the increase in S68 PLM phosphorylation induced by histamine alone. There was a highly signifi cant inverse correlation between S68 PLM phosphorylation and force ( fi g. 4 ). This suggests that S68 PLM phosphorylation could be involved in cAMP-dependent relaxation. However, such a correlation does not defi nitively establish PLM as a determinant of the resulting relaxation. Further experiments are planned to evaluate whether S68 PLM phosphorylation is a regulator of smooth muscle force.
Physiology of PLM Phosphorylation in Smooth Muscle
We also evaluated whether cGMP-mediated relaxation involves S68 PLM phosphorylation. Many substrates for PKA are also substrates for protein kinase G. We fi nd that nitroglycerin-induced relaxation was not associated with changes in S68 PLM phosphorylation ( fi g. 5 ). This suggests that PLM can only be involved in cAMP-mediated relaxation.
There is a physical and functional association of PLM with membrane ion transporters such as the Na,K-ATPase [6, 7] and the Na-Ca exchanger (NCX1) [8, 9] . Based on our data and these studies, we hypothesize that PLM may be involved in smooth muscle regulation via regulation of Na,K-ATPase. ␤ 2 -Adrenergic stimuli, presumptively via increasing [cAMP], increased Na,K-ATPase activity in smooth muscle [34] . Fay and Moore [35] found that ␤ 2 -adrenergic stimuli in smooth muscle reduced [Na + ] i , suggesting an increase in Na,K-ATPase activity. However, Borin [36] found that cAMP increased [Na + ] i in isolated smooth muscle cells. Na,K-ATPase knockout mice have been made, but are lethal, with death occurring just after birth. Neonatal aortae from ␣ 2 -Na,K-ATPase -/-mice were less sensitive to forskolin-induced relaxation when compared with ␣ 2 -Na,K-ATPase +/+ mice [37] . We also fi nd that forskolin inhibited the swine carotid contraction induced by removal of [ ] i is reduced. We plan to study more direct measures of Na,KATPase activity in the future. Nevertheless, these data support the hypothesis that cAMP-mediated relaxation at least partially involves Na,K-ATPase, likely by increasing its activity.
Specifi cally, we hypothesize that PKA-mediated phosphorylation of PLM on S68 increases the activity of Na,K-ATPase. Since Na,K-ATPase moves 3 Na + outward and 2 K + inward for every ATP consumed, it will produce a small hyperpolarization from the excess outward Na + ] i and cause smooth muscle relaxation; however, it would be associated with increased Ca 2+ effl ux rather than the decrease in Ca 2+ infl ux expected with hyperpolarization. We found that forskolin induced a hyperpolarization in rat tail artery [23] and a decrease in Mn 2+ infl ux in swine carotid artery [39] , suggesting that hyperpolarization may be the dominant mechanism in some smooth muscles.
PLM has a role in the regulation of cardiac contractility by [Ca 2+ ] as well. In cultured rat heart myocytes, the myocytes near an area of infarction have an abnormally blunted contractile response to extracellular Ca 2+ ([Ca 2+ ] o ) [40] . Overexpression of PLM produces myocytes with a blunted [Ca 2+ ] o response similar to those observed after myocardial infarction [28] . Intriguingly, PLM is one of a few genes whose expression level rises after myocardial infarction [41] , suggesting that PLM could be the mediator of the blunted [Ca 2+ ] o response. If NCX1, the cardiac Na-Ca exchanger, is over expressed in peri-infarction myocytes, a normal [Ca 2+ ] o response is observed [42] . A unifying explanation would be that PLM inhibits NCX1. Supporting this were fi ndings that PLM overexpression reduced currents through NCX1 and slowed the decline in [Ca 2+ ] i after the release of sarcoplasmic reticulum stores with caffeine [28] . Co-overexpression of NCX1 with PLM restored the currents and Ca 2+ dynamics to normal [8] . Moreover, reduction of PLM expression using anti-sense oligonucleotides increased NCX1 currents and sped the decline in [Ca 2+ ] i after caffeine [9] . Most recently, Ahlers et al. [43] found a physical and functional interaction between PLM and NCX1 co-expressed in HEK293 cells. The importance of S68, the site of PKA phosphorylation, was underscored by the fi nding that a phosphodeficient PLM mutant S68A lost the ability to inhibit Na-Ca exchange despite persistent physical association.
These data demonstrate that PLM is functional and present in smooth muscle and is phosphorylated by physiologic stimuli. We propose that S68 PLM phosphorylation may have a role in cAMP-, but not cGMP-mediated smooth muscle relaxation, possibly by activation of the Na,K-ATPase activity. The data also demonstrate relative specifi city for the C2 and CP68 PLM antibodies for dephosphorylated and S68 phosphorylated PLM, respectively.
